Skip to Content

Generic Biaxin XL Availability

See also: Generic Biaxin

Biaxin XL is a brand name of clarithromycin, approved by the FDA in the following formulation(s):

BIAXIN XL (clarithromycin - tablet, extended release;oral)

  • Manufacturer: ABBVIE
    Approval date: March 3, 2000
    Strength(s): 500MG

All of the above formulations have been discontinued.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Biaxin XL. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Extended release formulations of erythromycin derivatives
    Patent 6,010,718
    Issued: January 4, 2000
    Inventor(s): Al-Razzak; Laman & Crampton; Sheri L. & Gustavson; Linda E. & Hui; Ho-Wah & Milman; Nelly & Semla; Susan J.
    Assignee(s): Abbott Laboratories
    Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower C.sub.max in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
    Patent expiration dates:
    • April 11, 2017
      ✓ 
      Patent use: TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS
      ✓ 
      Drug product
  • Extended release formulations of erythromycin derivatives
    Patent 6,551,616
    Issued: April 22, 2003
    Inventor(s): Gerard F.; Notario & Robert N.; Palmer & Richard C.; Hom & Jie; Zhang & Karen J.; Devcich & Susan J.; Semla
    Assignee(s): Abbott Laboratories
    Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.
    Patent expiration dates:
    • June 15, 2017
      ✓ 
      Patent use: TREATMENT OF MILD TO MODERATE INFECTION CAUSED ABY SUSCEPTIBLE STRAINS

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
Hide